ПАРТАНАТОЗ И ОНКОГЕНЕЗ ПЕЧЕНИ
Аннотация
В обзоре представлена информация о редком виде программируемой неапоптотической гибели клеток – партанатозе, механизмах его развития, активации и последствиях, включая онкогенез. Исследователям, принявшим решение провести научные изыскания по партанатозу, предлагаются для рассмотрения разные биологические, биохимические и иммунологические маркеры партанатоза, связанные с повреждением ядерного аппарата, митохондрий и других органелл клетки. Отдельно представлена роль партанатоза в развитии гепатоцеллюлярной карциномы, связанной с HBV-инфекцией.
Литература
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer. The molecular machinery of regulated cell death. Cell Res. 2019;29(5):347-364. https://doi.org/10.1038/s41422-019-0164-5.
Tsyrkunov VM, Andreev VP, Kravchuk RI. Lizosomalno-zavisimaja gibel gepatocitov pri hronicheskom gepatite S [Lysosomal dependent death of hepatocytes in chronic hepatitis C]. Gepatologija i gastrojenterologija [Hepatology and Gastroenterology]. 2020;4(1):34-44. https://doi.org/10.25298/2616-5546-2020-4-1-34-44. https://elibrary.ru/oxmdyy. (Russian).
Tsyrkunov VM, Andreev VP, Prokopchik NI, Kravchuk RI. Vidy programmiruemoj gibeli gepatocitov pri hronicheskom gepatite S [Types of programmable hepatocytes death in chronic hepatitis С]. Gepatologija i gastrojenterologija [Hepatology and Gastroenterology]. 2020;4(2):109-125. https://doi.org/10.25298/2616-5546-2020-4-2-109-125. https://elibrary.ru/hvmiig. (Russian).
David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009;14(3):1116-28. https://doi.org/10.2741/3297.
Delettre C, Yuste VJ, Moubarak RS, Bras M, Lesbordes-Brion JC, Petres S, Bellalou J, Susin SA. AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer. J Biol Chem. 2006;281(10):6413-27. https://doi.org/10.1074/jbc.M509884200.
Wang H, Yu SW, Koh DW, Lew J, Coombs C, Bowers W, Federoff HJ, Poirier GG, Dawson TM, Dawson VL. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci. 2004;24(48):10963-73. https://doi.org/10.1523/JNEUROSCI.3461-04.2004.
Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents – A recent update. Eur J Med Chem. 2019;165:198-215. https://doi.org/10.1016/j.ejmech.2019.01.024.
Wang R, Li C, Qiao P, Xue Y, Zheng X, Chen H, Zeng X, Liu W, Boldogh I, Ba X. OGG1-initiated base excision repair exacerbates oxidative stress-induced parthanatos. Cell Death Dis. 2018;9(6):628. https://doi.org/10.1038/s41419-018-0680-0.
Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008;1147:233-241. https://doi.org/10.1196/annals.1427.014.
Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, Poirier GG, Dawson VL, Dawson TM. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011;4(167):ra20. https://doi.org/10.1126/scisignal.2000902.
Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A. 2006;103(48):18314-9. https://doi.org/10.1073/pnas.0606528103.
Zong W, Gong Y, Sun W, Li T, Wang ZQ. PARP1: Liaison of Chromatin Remodeling and Transcription. Cancers (Basel). 2022;14(17):4162. https://doi.org/10.3390/cancers14174162.
Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK. β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014;5:e1230. https://doi.org/10.1038/cddis.2014.202.
Aizawa S, Brar G, Tsukamoto. Cell Death and Liver Disease. Gut Liver. 2020;14(1):20-29. https://doi.org/10.5009/gnl18486.
Paturel A, Hall J, Chemin I. Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy. Cancers (Basel). 2022;14(15):3806. https://doi.org/10.3390/cancers14153806.
Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727-738. https://doi.org/10.1016/j.jhep.2017.05.014.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, et al. Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486-541. https://doi.org/10.1038/s41418-017-0012-4.
Wang Y, An R, Umanah GK, Park H, Nambiar K, Eacker SM, Kim B, Bao L, Harraz MM, Chang C, Chen R, Wang JE, Kam TI, Jeong JS, Xie Z, Neifert S, Qian J, Andrabi SA, Blackshaw S, Zhu H, Song H, Ming GL, Dawson VL, Dawson TM. A nuclease that mediates cell death induced by DNA damage and poly (ADPribose) polymerase-1. Science. Science. 2016;354(6308):aad6872. https://doi.org/10.1126/science.aad6872.aad6872.
Zhang Y, Wu K, Liu Y, Sun S, Shao Y, Li Q, Sui X, Duan C. UHRF2 promotes the malignancy of hepatocellular carcinoma by PARP1 mediated autophagy. Cell Signal. 2023;109:110782. https://doi.org/10.1016/j.cellsig.2023.110782.
Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci. 2019;64(10):2878-2892. https://doi.org/10.1007/s10620-019-05608-4.
Ward JF. Complexity of damage produced by ionizing radiation. Cold Spring Harb Symp Quant Biol. 2000;65:377-82. https://doi.org/10.1101/sqb.2000.65.377.
Funato K, Otsuka M, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, Fujishiro M. Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors. Biochem Biophys Res Commun. 2022;607:89-95. https://doi.org/10.1016/j.bbrc.2022.03.137.
Zhang X, Wang Y, A G, Qu C, Chen J. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Chen. Front Immunol. 2021;12:721030. https://doi.org/10.3389/fimmu.2021.721030.
Diagnostika jekspressii PD-L1 [Internet]. Available from: http://www.cancergenome.ru/mutations/PD-L1/ (Russian).
